|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
C4 Therapeutics, Inc. (CCCC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
49,280,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile C4 Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Co.'s primary product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
5,667 |
Total Buy Value |
$0 |
$0 |
$0 |
$31,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fisher Stewart |
Chief Scientific Officer |
|
2021-07-29 |
4 |
AS |
$45.00 |
$2,259,631 |
D/D |
(50,211) |
57,905 |
|
- |
|
Crystal Adam |
Chief Medical Officer |
|
2021-07-29 |
4 |
AS |
$45.00 |
$675,000 |
D/D |
(15,000) |
0 |
|
- |
|
Crystal Adam |
Chief Medical Officer |
|
2021-07-29 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
15,000 |
|
- |
|
Siegel Jolie |
Chief Legal Officer |
|
2021-07-29 |
4 |
AS |
$45.00 |
$562,500 |
D/D |
(12,500) |
0 |
|
- |
|
Siegel Jolie |
Chief Legal Officer |
|
2021-07-29 |
4 |
OE |
$4.98 |
$62,250 |
D/D |
12,500 |
12,500 |
|
- |
|
Salter Malcolm |
Director |
|
2021-07-16 |
4 |
AS |
$37.37 |
$28,214 |
D/D |
(755) |
14,427 |
|
- |
|
Dubin Glenn |
Director |
|
2021-07-02 |
4 |
A |
$39.72 |
$6,236 |
D/D |
157 |
157 |
|
- |
|
Anderson Kenneth Carl |
Director |
|
2021-07-02 |
4 |
A |
$39.72 |
$8,738 |
D/D |
220 |
85,366 |
|
- |
|
Cohen Marc A |
Director |
|
2021-07-02 |
4 |
A |
$39.72 |
$20,734 |
D/D |
522 |
6,641 |
|
- |
|
Cohen Alain J |
Director |
|
2021-07-02 |
4 |
A |
$39.72 |
$9,970 |
D/D |
251 |
517 |
|
- |
|
Salter Malcolm |
Director |
|
2021-07-02 |
4 |
A |
$39.72 |
$13,465 |
D/D |
339 |
15,182 |
|
- |
|
Crystal Adam |
Chief Medical Officer |
|
2021-07-01 |
4 |
AS |
$37.93 |
$569,666 |
D/D |
(15,000) |
0 |
|
- |
|
Crystal Adam |
Chief Medical Officer |
|
2021-07-01 |
4 |
OE |
$6.50 |
$97,500 |
D/D |
15,000 |
15,000 |
|
- |
|
Salter Malcolm |
Director |
|
2021-06-18 |
4 |
AS |
$37.19 |
$28,078 |
D/D |
(755) |
14,843 |
|
- |
|
Cohen Alain J |
Director |
|
2021-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
22,598 |
1,741,930 |
|
- |
|
Cohen Alain J |
Director |
|
2021-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
61,877 |
62,143 |
|
- |
|
Cohen Marc A |
Director |
|
2021-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
22,598 |
1,874,805 |
|
- |
|
Cohen Marc A |
Director |
|
2021-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
92,817 |
98,936 |
|
- |
|
Salter Malcolm |
Director |
|
2021-05-21 |
4 |
AS |
$37.12 |
$28,026 |
D/D |
(755) |
15,598 |
|
- |
|
Anderson Kenneth Carl |
Director |
|
2021-04-14 |
4 |
OE |
$2.11 |
$2,774 |
D/D |
711 |
85,146 |
|
- |
|
Anderson Kenneth Carl |
Director |
|
2021-04-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,278 |
47,316 |
|
- |
|
Anderson Kenneth Carl |
Director |
|
2021-04-13 |
4 |
GA |
$0.00 |
$0 |
D/D |
2,278 |
84,435 |
|
- |
|
Dubin Glenn |
Director |
|
2021-03-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
790,607 |
|
- |
|
Cohen Marc A |
Director |
|
2021-02-18 |
4 |
OE |
$2.11 |
$1,131 |
D/D |
536 |
5,566 |
|
- |
|
Fisher Stewart |
Chief Scientific Officer |
|
2021-02-03 |
4 |
OE |
$2.11 |
$26,999 |
D/D |
8,300 |
108,116 |
|
- |
|
166 Records found
|
|
Page 6 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|